Product Description
Mechanisms of Action: TNF Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Erythema|Arthritis, Psoriatic|Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Not Applicable | P3 |
Completed |
Psoriasis|Erythema |
2006-03-23 |
|
2004-000530-37 | P3 |
Completed |
Erythema|Psoriasis |
2006-03-01 |
|
NCT00090129 | P3 |
Terminated |
Arthritis, Psoriatic|Psoriasis |
2005-06-01 |